Ticlopidine-induced severe agranulocytosis after the placement of coronary artery stent--a case report.
Ticlopidine is an oral antiplatelet agent frequently utilized in the treatment of cerebrovascular disease. It is rarely associated with severe bone marrow suppression. A case of an elderly woman is reported who developed febrile agranulocytosis two months after commencing ticlopidine but who had a favorable outcome after cessation of that drug and treatment with granulocyte colony-stimulating factor (G-CSF). All patients should have regular monitoring of their blood counts during therapy with ticlopidine.
Sari
R
R
Inonu University, School of Medicine, Department of Internal Medicine, Turgut Ozal Medical Center, Malatya, Turkey. drsari@hotmail.com
Sevinc
A
A
Buyukberber
S
S
D000380:Agranulocytosis / Q000139:chemically induced* / Q000188:drug therapy*; D003327:Coronary Disease / Q000628:therapy; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D011183:Postoperative Complications; D015607:Stents; D013988:Ticlopidine / Q000009:adverse effects*
D010975:Platelet Aggregation Inhibitors; D016179:Granulocyte Colony-Stimulating Factor; D013988:Ticlopidine